On Nov. 3, 2021, Novavax announced the company had filed for provisional approval of the vaccine to the New Zealand Medicines and Medical Devices Safety Authority (Medsafe). The submission included clinical data from PREVENT-19, a pivotal Phase 3 trial of 30,000 participants in the U.S. and Mexico that demonstrated 100% protection against moderate and severe disease and 90.4% efficacy overall.